Focus: Edgewise Therapeutics is a public biotech company focused on small-molecule therapeutics for musculoskeletal diseases, particularly muscular dystrophies. Listed on NASDAQ (EWTX), the company operates from Boulder, Colorado with a specialized pipeline targeting rare genetic muscle disorders.
Profile data last refreshed 43m ago · AI intelligence enriched 2mo ago
Stable — net +2 jobs in 30d
6 added, 4 removed. Backfill posture.
Edgewise offers focused muscular dystrophy expertise and recent acquisition validation, but early-stage pipeline depth and cash burn create near-term career volatility; best fit for scientists willing to ride through acquisition integration.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Edgewise Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Edgewise Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 - PR Newswire
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 PR Newswire
Edgewise's 12-week heart treatment study gets a late-breaking slot in Munich - Stock Titan
Edgewise's 12-week heart treatment study gets a late-breaking slot in Munich Stock Titan
Edgewise Therapeutics: Servier Deal Creates A Self-Funded Cardiovascular Platform (EWTX) - Seeking Alpha
Edgewise Therapeutics: Servier Deal Creates A Self-Funded Cardiovascular Platform (EWTX) Seeking Alpha
Edgewise Therapeutics (EWTX) gives CSO 65K options at $43.56 - Stock Titan
Edgewise Therapeutics (EWTX) gives CSO 65K options at $43.56 Stock Titan
Edgewise (NASDAQ: EWTX) CBO gets 100K options vesting from 2026 - Stock Titan
Edgewise (NASDAQ: EWTX) CBO gets 100K options vesting from 2026 Stock Titan
Edgewise Therapeutics (EWTX) sets GC option price at $43.56 - Stock Titan
Edgewise Therapeutics (EWTX) sets GC option price at $43.56 Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo